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Background: Recently, the entity of retinal angiomatous
proliferation (RAP) as a subtype of exudative age-related
macular degeneration was described, but no treatment
options have been established as yet. The only two
therapeutic modalities being discussed are surgical lysis of
the feeding arteriole and draining venule, and the use of
photodynamic therapy combined with intravitreal triamcino-
lone injection.
Aim: To examine focal laser treatment of early extrafoveal
intraretinal neovascularisation of RAP.
Methods: Prospective case series. We included 13 consecu-
tive patients with an extrafoveal RAP stage I lesion. All
patients underwent a complete ophthalmic examination,
including fluorescein angiography and optical coherence
tomography (OCT) III before treatment and at 2 weeks, 1, 2
and 4 months afterwards. In cases with marked macular
oedema (.350 mm retinal thickening in OCT III, r = 12),
intravitreal injection of 4 mg triamcinolone was given before
focal laser treatment to reduce the oedema.
Results: This case series indicates anatomical improvement
or stabilisation in patients with an extrafoveal RAP lesion
after treatment. Initial visual acuity ranged from 0.1 to 0.6 on
the Snellen chart. By calculating logarithmic values, visual
acuity was seen to be improved in five cases (2 to 5 log lines),
deteriorated in four cases (22 to 5 log lines) and stabilised in
four cases (21 to +1 log line change). Exudation on
fluorescein angiography was stopped in 11 cases.
Conclusions: This preliminary case series suggests laser
photocoagulation combined with prior intravitreal triamci-
nolone injection as a viable treatment option for RAP stage I.
In cases with marked macular oedema, intravitreal triamci-
nolone injection improved visual acuity. For long-term
stabilisation, additional laser treatment is mandatory. These
preliminary results warrant a more detailed prospective
clinical trial.
T
he entity of retinal angiomatous proliferation (RAP) as a
subtype of age-related macular degeneration (ARMD)
was first described by Yannuzzi et al.1 This new type of
neovascular lesion in ARMD does not originate from the
choroid, but begins with intraretinal new vessels, extends to
the subretinal space and eventually communicates with new
choroidal vessels. Yannuzzi et al distinguished three different
stages that indicate deep intraretinal capillary proliferation
within the retina (intraretinal neovascularisation) as stage I.
This is typically characterised by multiple small intraretinal
haemorrhages and intraretinal oedema surrounding the core
of proliferating capillaries. It also includes hard exudates as
well as retinal–retinal anastomosis.
Stage II is classified as the extending of intraretinal
neovascularisation beyond the photoreceptor layer into the
subretinal space, and is called subretinal neovascularisation.
It may be combined with a pigment epithelium detachment
(PED). Stage III includes choroidal neovascularisation as well
as retinal choroidal anastomosis (RCA).
Since then, few studies have evaluated therapeutic options
for this new subtype of ARMD, and as yet there is no effective
treatment. Surgical ablation of RAP has been described in a
small number of patients with RAP stage II associated with
serous PED,2 and it has been shown that visual acuity
improved and macular thickening resolved. Other reports
showed benefit from combined photodynamic therapy (PDT)
with intravitreal triamcinolone in single cases.3 4 With regard
to the late stages of RAP such as choroidal neovascularisa-
tion, RCA and associated PED, the unique conviction in the
literature is a high risk for pigment epithelium tears caused
by PDT.5 The effects of triamcinolone injection are limited
and temporary. Recently, combined surgical ablation and
intravitreal triamcinolone for RAP stage III has been
reported.6 This treatment was safe and anatomically effective,
but recurrence after surgical ablation has been described by
another author.7
A literature search showed no studies evaluating treatment
options for RAP stage I.
The purpose of this study was to determine the effects of
laser photocoagulation in combination with prior triamcino-
lone injection on RAP stage I.
MATERIALS AND METHODS
We prospectively included 13 consecutive patients with RAP
stage I at least in one eye. They were identified in the Ludwig-
Maximilians-University Munich, ARMD outpatient clinic
between October 2004 and May 2005 and showed typical
signs of ARMD, including soft Drusen, retinal pigment
epithelium changes or atrophy.
Patients were both male and female (3 men and 10
women); their age ranged from 61 to 95 years (average age
75 years). None of their eyes had received any treatment
before inclusion into our study.
To be eligible, patients were required to have an extrafoveal
RAP lesion stage I (> 500 mm from the fovea), classified by
clinical slit-lamp biomicroscopy by one experienced examiner
(MU), fluorescein angiography and optical coherence tomo-
graphy (OCT) III. Other neovascular maculopathies such
as pathological myopia, angioid streaks, inflammatory
Abbreviations: ARMD, age-related macular degeneration; BCVA, best-
corrected visual acuity; CRA, chorioretinal atrophy; FVS, fibrovascular
scar; IVTA, intravitreal triamcinolone; MAR, minimum angle of
resolution; OCT, optical coherence tomography; PDT, photodynamic
therapy; PED, pigment epithelium detachment; RAP, retinal angiomatous
proliferation; RCA, retinal choroidal anastomosis
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chorioretinal diseases, tumours or trauma were not included.
Also excluded were late stages of RAP such as RCA or serous
PED.
According to these criteria, 13 eyes of 13 patients were
included. All patients underwent a complete ophthalmic
examination, including fluorescein angiography and OCT III
at 2 weeks, 1, 2 and 4 months afterwards. Angiography was
carried out with a Heidelberg Retina Angiograph II
(Heidelberg Engineering, Heidelberg, Germany) at 30 s, 1, 3
and 5.5 min after injection of 10 ml 10% fluorescein (Alcon,
Texas, USA) into the cubital vein. In the case of marked
macular oedema (.350 mm retinal thickening in OCT III, 12
of 13 cases), an intravitreal triamcinolone injection (4 mg)
was given. The decision for laser treatment was based on the
clinical findings and fluorescein angiography by one retinal
specialist (MU). Photocoagulation was also carried out by
one retinal specialist (MU) by means of a Humphrey Visulas
532 nm laser (Zeiss, Jena, Germany) and the ‘‘Area
Centralis’’ lens (Volk, Mentor, Ohio) after a mean interval
of 4 weeks. The number of spots applied varied from 9 to 36
(mean = 19 spots). The power was from 150 to 300 mW
(mean = 266 mW), with a spot size of 200 mm. The exposure
time varied from 200 to 300 ms.
Follow-up visits were performed at 2 weeks after laser
treatment and at 1, 2 and 4 months after the treatment. All
follow-up visits included best-corrected visual acuity (BCVA)
with a Snellen chart at 6 months, full clinical examination
with slit-lamp biomicroscopy, fluorescein angiography, opti-
cal coherence tomography and fundus photography. All
examinations were also carried out on the fellow eye.
The main outcome measure was a change in visual acuity .
Improvement was defined as a change in visual acuity from 2
to 5 log lines, stabilisation by change in visual acuity from21
to +1 log line, and deterioration was classified as a loss of 22
to 25 log lines.
Additionally, angiographic exudation was analysed.
RESULTS
In one case, laser photocoagulation had to be repeated to
achieve complete cessation of exudation and stabilisation of
visual acuity. Another case showed persistent exudation and
leakage, with extension into the subfoveal area. In this case,
PDT was successfully carried out.
One patient underwent intravitreal triamcinolone injection
and PDT on the fellow eye for advanced RAP.
Another case showed rapid deterioration in the fellow eye,
which progressed from RAP stage I to III during the period of
review.
During the period of review, only one study eye progressed
to RAP stage III. The other eyes with deterioration in visual
acuity, nevertheless, showed stabilised angiographic findings.
There were no complications related to intravitreal injec-
tion or laser treatment.
Visual acuity
This study showed visual improvement in six patients. In
four patients, visual acuity remained unchanged and three
patients showed deterioration. At baseline, BCVA ranged
from logarithm of minimum angle of resolution (log MAR) 1
to log MAR 0.2 (decimal equivalent 0.1–0.6 Snellen scale). At
the 1-month and 4-month visits the BCVA ranged from log
MAR 1.3 to log MAR 0.2, whereas the average BCVA changed
from log MAR 0.65 to log MAR 0.6 at the 1-month visit and
to log MAR 0.54 at the 4-month visit (fig 1).
The BCVA improved in six patients (46%) by 2–8 log lines
(average gain in this group was 3.8 log lines, decimal
equivalent 0.2–1.0 Snellen chart). The BCVA stabilised in four
patients (31%) (no log line change in visual acuity, decimal
equivalent 0.2–0.6 Snellen chart). In three patients (23%) the
BCVA decreased by 2–5 log lines ( average loss in this group
was 3.6 log lines, decimal equivalent 0.05–0.1 Snellen chart
(table 1).
Fluorescein angiography findings
Exudation on fluorescein angiography was completely
stopped in 11 of 13 (85%) eyes at the 4-month visit. Even
in the group with deterioration of visual acuity, we observed
stable angiographic findings.
Table 1 Visual acuity (logarithm of minimum angle of resolution units) of patients with retinal angiomatous proliferation stage I
















1 82 1 1 1 0.4 0.7 3 RAP stage I of
fellow eye
2 76 0.5 0 0 0 0 5
3 74 0.7 0.7 0.7 0.7 0.7 0
4 80 1 0.9 1.3 1.3 1.3 23
5 76 0.7 1 1 1 1 23
6 61 1 0.3 0.4 0.2 0.2 8
7 66 0.7 0.4 0.4 0.4 0.4 3
8 63 0.5 0.7 1 0.8 1 25 PDT 1
9 72 0.8 1 0.6 2
10 71 0.2 0.2 0.2 0.3 0.2 0
11 78 0.5 0.4 0.3 0.2 0.3 2
12 87 0.3 0.4 0.3 0.4 0.2 1 IVTA 2
13 95 0.6 0.5 0.7 0.5 21
Mean 0.65 0.57 0.6 0.57 0.54
The table also includes the age of the patients and complications, as well as eventual further additional treatment.
IVTA, intravitreal triamcinolone; MAR, minimum angle of resolution; PDT, photodynamic therapy; RAP, retinal angiomatous proliferation; VA, visual acuity.
Table 2 Fellow eyes of patients under study and clinical
stage of age-related macular degeneration
Clinical stage of ARMD Number of eyes
ARMD with mild Drusen 5
RAP stage II or III 3
FVS 2
CRA 3
ARMD, age-related macular degeneration; CRA, chorioretinal atrophy;
FVS, fibrovascular scar; RAP, retinal angiomatous proliferation.
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In one eye with unchanged BCVA, angiographic extension
of neovascularisation to the subfoveal area was noted. In this
case, additional PDT was successful and the visual acuity
stabilised.
Another patient showed recurrent exudation at the edge of
the laser scar with intraretinal oedema at the 4-month visit.
Additional intravitreal triamcinolone injection and photo-
coagulation were scheduled in this case.
Fellow eyes
The study eyes with treated RAP stage I lesion had better
function in 8 (62%) eyes compared with their fellow eyes. The
fellow eyes had either RAP lesions (stage II or III) or a
fibrovascular scar (table 2).
DISCUSSION
This study presents a novel treatment option in retinal
angiomatous proliferation stage I. As the neovascular origin
of the lesion is in the deep intraretinal vascular plexus,
photocoagulation of extrafoveal lesions was carried out to
prevent progression to RAP stage II or III.1 This led to
stabilisation or improvement of visual acuity and stable
angiographic findings in most of the eyes.
Thermal laser photocoagulation has been considered
unfavourable with poor visual outcome previously because
it does not spare retinal pigment epithelium.2 Especially in
eyes with associated PED, studies suggest little benefit.8–10
Only one case reported laser treatment for RAP with




Figure 1 (A–D) Case 2: A 76-year-old woman with retinal angiomatous proliferation (RAP) stage I with extrafoveal leakage in the right eye. Visual
acuity was 0.3 (logarithm of minimum angle of resolution (logMAR) 0.5). (A, B) Angiography as well as optical coherence tomography (OCT) findings
showed extrafoveal leakage in combination with intraretinal oedema. Clinically, we found superficial intraretinal haemorrhages and hard exudates.
(C, D) Findings 4 months after intravitreal injection of triamcinolone and consecutive laser treatment. The visual acuity changed from 0.3 to 1.0 (log
MAR 0). There was no exudation in fluorescein angiography and no intraretinal oedema on OCT. (E) Fundus photography of treated RAP stage I lesion
after 4 months. (F) Fellow eye with RAP stage III.
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classification of RAP into different stages, there have been no
further trials that evaluated conventional laser photocoagu-
lation as a treatment option for extrafoveal stage I RAP
lesions. However, the therapeutic gold standard for small
extrafoveal classic choroidal neovascularisation is thermal
photocoagulation.12
According to the results of this preliminary study, early
detection and treatment of RAP stage I are recommended, and
a high level of visual acuity and quality of life can be sustained.
Early detection is of most importance. These patients rarely
had distortion, and as the RAP tends to form in an extrafoveal
part of the macular area, only a mild decrease in visual acuity
was reported. Presentation in the clinic is usually because of a
RAP stage II or III lesion in the fellow eye. Yannuzzi et al1
observed RAP lesions to be bilateral. They begin with small
intraretinal, extrafoveal new vessels. Therefore it is mandatory
to examine the fellow eye for early changes.
We do acknowledge that our study presents only a small
number of patients and has a limited period of review.
Nevertheless, it was shown that extrafoveal RAP stage I can
benefit from combined treatment with intravitreal triamci-
nolone and thermal laser photocoagulation. This justifies a
more detailed and prospective clinical trial. The treatment of
RAP stage I may prevent the progression to RAP stage II and
III for some time.
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